Intellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low – What’s Next?

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s stock price hit a new 52-week low on Tuesday . The stock traded as low as $9.21 and last traded at $9.35, with a volume of 302791 shares changing hands. The stock had previously closed at $9.58.

Analysts Set New Price Targets

Several research analysts have commented on NTLA shares. Chardan Capital upped their target price on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Canaccord Genuity Group reiterated a “buy” rating and set a $90.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Citigroup lowered their target price on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. BMO Capital Markets reduced their price target on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Finally, Barclays decreased their price target on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $48.71.

Intellia Therapeutics Stock Up 3.3 %

The business’s fifty day moving average is $11.51 and its 200 day moving average is $16.69.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 29,000 shares of company stock worth $352,551 in the last three months. 3.20% of the stock is currently owned by insiders.

Institutional Trading of Intellia Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Whipplewood Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the fourth quarter valued at approximately $40,000. Eastern Bank purchased a new position in Intellia Therapeutics during the 3rd quarter worth approximately $41,000. Resona Asset Management Co. Ltd. acquired a new stake in Intellia Therapeutics during the 4th quarter valued at $43,000. Jones Financial Companies Lllp lifted its holdings in shares of Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after purchasing an additional 2,280 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of Intellia Therapeutics in the third quarter worth $54,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.